(NASDAQ: GH) Guardant Health's forecast annual revenue growth rate of 29.1% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.02%.
Guardant Health's revenue in 2026 is $982,021,000.On average, 30 Wall Street analysts forecast GH's revenue for 2026 to be $171,833,277,710, with the lowest GH revenue forecast at $162,257,835,517, and the highest GH revenue forecast at $179,047,651,965. On average, 30 Wall Street analysts forecast GH's revenue for 2027 to be $220,497,511,321, with the lowest GH revenue forecast at $199,247,899,879, and the highest GH revenue forecast at $252,371,928,484.
In 2028, GH is forecast to generate $279,261,868,889 in revenue, with the lowest revenue forecast at $240,697,759,235 and the highest revenue forecast at $311,136,286,052.